about
Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survivalAnti-prion activity of an RNA aptamer and its structural basisNeuroradiology of human prion diseases, diagnosis and differential diagnosis.Prion protein interaction with stress-inducible protein 1 enhances neuronal protein synthesis via mTORInfluence of Mabs on PrP(Sc) formation using in vitro and cell-free systemsPrions.Prion protein-specific antibodies-development, modes of action and therapeutics applicationComparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cellsAntiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.Characterization of four new monoclonal antibodies against the distal N-terminal region of PrP(c).A Single Subcutaneous Injection of Cellulose Ethers Administered Long before Infection Confers Sustained Protection against Prion Diseases in RodentsPharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.Comparing the energy landscapes for native folding and aggregation of PrP.Therapies for human prion diseasesPrion protein-coated magnetic beads: synthesis, characterization and development of a new ligands screening method.Laboratory activities involving transmissible spongiform encephalopathy causing agents: risk assessment and biosafety recommendations in Belgium.Efficacy and mechanism of a glycoside compound inhibiting abnormal prion protein formation in prion-infected cells: implications of interferon and phosphodiesterase 4D-interacting protein.Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases.An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein.Treatment of SMB-S15 Cells with Resveratrol Efficiently Removes the PrP(Sc) Accumulation In Vitro and Prion Infectivity In Vivo.Insights from Therapeutic Studies for PrP Prion Disease.Pyrene conjugation and spectroscopic analysis of hydroxypropyl methylcellulose compounds successfully demonstrated a local dielectric difference associated with in vivo anti-prion activity.Synthesis of an (11) C-labeled antiprion GN8 derivative and evaluation of its brain uptake by positron emission tomography.Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead CompoundsWhat Is Our Current Understanding of PrPSc-Associated Neurotoxicity and Its Molecular Underpinnings?A promising anti-prion trimethoxychalcone binds to the globular domain of PrP(C) and changes its cellular location.Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrPC.
P2860
Q27313215-93309A05-8D65-458C-A867-60C1A6B1EEA3Q27675235-F043FE67-4B9E-4E99-80D3-DBD0C0C34550Q31155802-3E97C637-38C8-45CB-9201-27D516FA8D0EQ34059200-A96C0232-5D3B-4F48-8E82-81D5B2AA637EQ34358708-CA5B6F95-D307-4727-A0E8-233F43E849C4Q34413061-81802520-6CC0-404B-8788-23D115A0693FQ34423386-8412D4F2-9BDD-448F-A9ED-A6D31605FFF8Q34436476-57CF9ED1-A6AA-46C0-A3C9-22537C7955B4Q35030768-BD7DD4C6-A6B4-4B11-A7BD-FF1A641CE9C3Q35205070-32A479FB-DAEB-4ADF-AD50-BD792B46CAC4Q36223572-A1E29216-7CF3-4F95-A578-98966530539CQ36806526-B3141CCA-2499-4BEC-A08B-F8EAB57D4818Q37167847-56D98725-6B2F-41EA-A1C8-5FB0AF2F025EQ37199225-69576E97-74AF-49CE-B642-A482D807E3BBQ37262131-7375BDAE-6FA6-447C-AC9D-C98AA193BC81Q37523329-18660FC5-6AF5-47D2-9B2C-6DBC5E79558EQ37713907-C5970D15-DE51-4128-8954-EAA6BF3823E7Q38234645-84B59443-16BD-4540-B78B-813E632929C3Q38634933-11779B7D-2CFA-4669-8BFD-5FE3FACA6A08Q38830007-C306A789-1AB6-44A8-AB00-E7B5E9A14303Q39005891-F4D3D710-2B73-418E-9D1D-5296F3FBF7BFQ41997119-FDB1E85F-CF8B-438C-90F7-F5471BFD9E3FQ42261396-596782FD-AD75-464E-A85F-2CEE36498D46Q42559957-2D592425-1B01-443A-8A70-B158A1B62CFCQ47342598-187BD21F-5652-47CF-8772-75E525E8F3F9Q47406923-43F0D06C-1A9E-43AA-88D7-72092DF497F2Q49823885-C61B2415-8960-49EA-B76C-812A49F36A82
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Recent advances in prion chemotherapeutics.
@ast
Recent advances in prion chemotherapeutics.
@en
type
label
Recent advances in prion chemotherapeutics.
@ast
Recent advances in prion chemotherapeutics.
@en
prefLabel
Recent advances in prion chemotherapeutics.
@ast
Recent advances in prion chemotherapeutics.
@en
P2860
P1476
Recent advances in prion chemotherapeutics.
@en
P2093
Valerie L Sim
P2860
P356
10.2174/1871526510909010081
P577
2009-02-01T00:00:00Z